Evidence map›Paper›PMID 32046158›Full record

ReviewInternational journal of molecular sciences2020

A New and Integral Approach to the Etiopathogenesis and Treatment of Breast Cancer Based upon Its Hydrogen Ion Dynamics.

Salvador Harguindey, Khalid Alfarouk, Julián Polo Orozco, Kevin Hardonniere, Daniel Stanciu, Stefano Fais, Jesús Devesa

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Exploring monocarboxylate transporter inhibition for cancer treatment.Exploration of targeted anti-tumor therapy · 2024
    Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Targeting the pH Paradigm at the Bedside: A Practical Approach.International journal of molecular sciences · 2020
    Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Salvador HarguindeyInstitute of Clinical Biology and Metabolism, Postas 13, 01004 Vitoria, Spain.
Khalid AlfaroukAl-Ghad International Colleges for Applied Medical Sciences, Al-Madinah Al-Munawarah, Saudi Arabia and Alfarouk Biomedical Research LLC, Tampa, FL 33617, USA.
Julián Polo OrozcoInstitute of Clinical Biology and Metabolism, Postas 13, 01004 Vitoria, Spain.
Kevin HardonniereDepartment of Inflammation, Microbiome and Immunosurveillance, Université Paris-Saclay, Inserm, 92290, Châtenay-Malabry, France.
Daniel StanciuScientific Direction, MCS Foundation for Life, 5623KR Eindhoven, The Netherlands.
Stefano FaisDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità (National Institute of Health), Viale Regina Elena, 299, 00161 Rome, Italy.
Jesús DevesaScientific Direction, Foltra Medical Centre, Travesía de Montouto 24, 15886 Teo, Spain.

Funding

Mercedes Castresana Foundation. 2019-b. Association for Proton Research and Treatment 2019
6 · The paper itself

Abstract

Despite all efforts, the treatment of breast cancer (BC) cannot be considered to be a success story. The advances in surgery, chemotherapy and radiotherapy have not been sufficient at all. Indeed, the accumulated experience clearly indicates that new perspectives and non-main stream approaches are needed to better characterize the etiopathogenesis and treatment of this disease. This contribution deals with how the new pH-centric anticancer paradigm plays a fundamental role in reaching a more integral understanding of the etiology, pathogenesis, and treatment of this multifactorial disease. For the first time, the armamentarium available for the treatment of the different types and phases of BC is approached here from a Unitarian perspective-based upon the hydrogen ion dynamics of cancer. The wide-ranged pH-related molecular, biochemical and metabolic model is able to embrace most of the fields and subfields of breast cancer etiopathogenesis and treatment. This single and integrated approach allows advancing towards a unidirectional, concerted and synergistic program of treatment. Further efforts in this line are likely to first improve the therapeutics of each subtype of this tumor and every individual patient in every phase of the disease.

Indexed as

ProtonsAnimalsAntineoplastic AgentsBreast NeoplasmsDrug Resistance, NeoplasmFemaleHumansProton Pump InhibitorsProton PumpsTumor MicroenvironmentAntineoplastic AgentsProton Pump InhibitorsProton PumpsProtonsbreast cancer etiologybreast cancer pathogenesisbreast cancer treatmentcancer proton reversalhydrogen ion dynamics of cancermultiple drug resistance (MDR) integral approachpH and breast cancerpH-centric anticancer paradigm

Identifiers

PMID32046158
PMCPMC7036897

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.